Immune Netw.  2013 Dec;13(6):235-239. 10.4110/in.2013.13.6.235.

Encapsulated Islet Transplantation: Strategies and Clinical Trials

• Buder B
• Alexander
• Krishnan R
• Chapman DW
• Lakey JR

• KMID: 2150783
• DOI: http://doi.org/10.4110/in.2013.13.6.235

Abstract

Encapsulation of tissue has been an area of intense research with a myriad number of therapeutic applications as diverse as cancer, tissue regeneration, and diabetes. In the case of diabetes, transplantation of pancreatic islets of Langerhans containing insulin-producing beta cells has shown promise toward a cure. However, anti-rejection therapy that is needed to sustain the transplanted tissue has numerous adverse effects, and the islets might still be damaged by immune processes. Furthermore, the profound scarcity of healthy human donor organs restricts the availability of islets for transplant. Islet encapsulation allows the protection of this tissue without the use of toxic medications, while also expanding the donor pool to include animal sources. Before the widespread application of this therapy, there are still issues that need to be resolved. There are many materials that can be used, differing shapes and sizes of capsules, and varied sources of islets to name a few variables that need to be considered. In this review, the current options for capsule generation, past animal and human studies, and future directions in this area of research are discussed.

Keyword

Transplantation; Diabetes

MeSH Terms

Animals
Capsules
Humans
Immunosuppression
Islets of Langerhans
Islets of Langerhans Transplantation*
Regeneration
Tissue Donors
Transplantation
Capsules

Reference

1. Gabardi S. Understanding risk evaluation and mitigation strategies in organ transplantation. Pharmacotherapy. 2011; 31:714–722.

2. Alves MG, Oliveira PF, Socorro S, Moreira PI. Impact of diabetes in blood-testis and blood-brain barriers: resemblances and differences. Curr Diabetes Rev. 2012; 8:401–412.

3. Salmons B, Gunzburg WH. Therapeutic application of cell microencapsulation in cancer. Adv Exp Med Biol. 2010; 670:92–103.

4. Thanos CG, Bintz B, Emerich DF. Microencapsulated choroid plexus epithelial cell transplants for repair of the brain. Adv Exp Med Biol. 2010; 670:80–91.

5. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev. 2001; 101:1869–1879.

6. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng Part B Rev. 2008; 14:149–165.

7. Peppas NA, Hilt JZ, Khadenhosseini A, Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater. 2006; 18:1345–1360.

8. Zimmermann H, Shirley SG, Zimmermann U. Alginate-based encapsulation of cells: past, present, and future. Curr Diab Rep. 2007; 7:314–320.

9. Safley SA, Cui H, Cauffiel S, Tucker-Burden C, Weber CJ. Biocompatibility and immune acceptance of adult porcine islets transplanted intraperitoneally in diabetic NOD mice in calcium alginate poly-L-lysine microcapsules versus barium alginate microcapsules without poly-L-lysine. J Diabetes Sci Technol. 2008; 2:760–767.

10. Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009; 32:1887–1889.

11. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 2007; 14:157–161.

12. Tarantal AF, Lee CC, Itkin-Ansari P. Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta). Transplantation. 2009; 88:38–41.

13. Cornolti R, Figliuzzi M, Remuzzi A. Effect of micro-and macroencapsulation on oxygen consumption by pancreatic islets. Cell Transplant. 2009; 18:195–201.

14. Lembert N, Wesche J, Petersen P, Doser M, Zschocke P, Becker HD, Ammon HP. Encapsulation of islets in rough surface, hydroxymethylated polysulfone capillaries stimulates VEGF release and promotes vascularization after transplantation. Cell Transplant. 2005; 14:97–108.

15. Vaithilingam V, Tuch BE. Islet transplantation and encapsulation: an update on recent developments. Rev Diabet Stud. 2011; 8:51–67.

16. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980; 210:908–910.

17. Souza YE, Chaib E, Lacerda PG, Crescenzi A, Bernal-Filho A, D'Albuquerque LA. Islet transplantation in rodents. Do encapsulated islets really work? Arq Gastroenterol. 2011; 48:146–152.

18. Suzuki K, Bonner-Weir S, Trivedi N, Yoon KH, Hollister-Lock J, Colton CK, Weir GC. Function and survival of macroencapsulated syngeneic islets transplanted into streptozocin-diabetic mice. Transplantation. 1998; 66:21–28.

19. Duvivier-Kali VF, Omer A, Lopez-Avalos MD, O'Neil JJ, Weir GC. Survival of microencapsulated adult pig islets in mice in spite of an antibody response. Am J Transplant. 2004; 4:1991–2000.

20. Soon-Shiong P, Feldman E, Nelson R, Heintz R, Yao Q, Yao Z, Zheng T, Merideth N, Skjak-Braek G, Espevik T, et al. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci U S A. 1993; 90:5843–5847.

21. Dufrane D, Goebbels RM, Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 2006; 81:1345–1353.

22. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 2010; 90:1054–1062.

23. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, Vasconcellos AV, Emerich DF, Thanos C, Bambra C. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc. 2005; 37:3505–3508.

24. Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, Harris M, Mendez R, Mendez R, Sandford PA, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994; 343:950–951.

25. Valdes-Gonzalez RA, Dorantes LM, Garibay GN, Bracho-Blanchet E, Mendez AJ, Dávila-Pérez R, Elliott RB, Terán L, White DJ. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol. 2005; 153:419–427.

26. Valdes-Gonzalez R, Rodriguez-Ventura AL, White DJ, Bracho-Blanchet E, Castillo A, Ramírez-González B, López-Santos MG, León-Mancilla BH, Dorantes LM. Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clin Exp Immunol. 2010; 162:537–542.

27. Elliot RB. Living Cell Technologies. Ltd, Prague: Czech Republic;2011.

28. Chhabra P, Brayman KL. Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation. J Transplant. 2011; 2011:637692.

29. Gao Q, Ma LL, Gao X, Yan W, Williams P, Yin DP. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant. 2010; 10:1588–1596.

30. Su J, Hu BH, Lowe WL Jr, Kaufman DB, Messersmith PB. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials. 2010; 31:308–314.

31. Bunger CM, Tiefenbach B, Jahnke A, Gerlach C, Freier T, Schmitz KP, Hopt UT, Schareck W, Klar E, de Vos P. Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids. Biomaterials. 2005; 26:2353–2360.

32. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes. 1993; 42:12–21.

33. Kuhtreiber WM, Lanza RP, Beyer AM, Kirkland KS, Chick WL. Relationship between insulin secretion and oxygen tension in hybrid diffusion chambers. ASAIO J. 1993; 39:M247–M251.

34. De Vos P, Van Straaten JF, Nieuwenhuizen AG, de Groot M, Ploeg RJ, De Haan BJ, Van Schilfgaarde R. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? Diabetes. 1999; 48:1381–1388.

35. Pedraza E, Coronel MM, Fraker CA, Ricordi C, Stabler CL. Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. Proc Natl Acad Sci U S A. 2012; 109:4245–4250.

36. Fritschy WM, Strubbe JH, Wolters GH, van Schilfgaarde R. Glucose tolerance and plasma insulin response to intravenous glucose infusion and test meal in rats with microencapsulated islet allografts. Diabetologia. 1991; 34:542–547.

37. Khanna O, Moya ML, Opara EC, Brey EM. Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor-1. J Biomed Mater Res A. 2010; 95:632–640.

38. Ludwig B, Ziegler CG, Schally AV, Richter C, Steffen A, Jabs N, Funk RH, Brendel MD, Block NL, Ehrhart-Bornstein M, Bornstein SR. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A. 2010; 107:12623–12628.